Soliris 300 MG/30 ML vial 30ML
Ended Awarded
- Contract number
- SPE2DR26FMDU1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,008
Award facts
- Contract value 100% obligated
- $41,008.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $41,008.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Soliris 300 mg/30 ml vials. The delivery order, issued on October 28, 2025, with an ultimate completion date of November 19, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as the awardee under its existing Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
The PPV-G GEN V contract held by DMS Pharmaceutical Group, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, with a completion date of December 31, 2036, featuring a 30-month base period and three 30-month option periods. This delivery order represents one of numerous purchases issued to the contractor by DLA's Medical Supply Chain division, reflecting DMS Pharmaceutical Group's established performance in supplying a comprehensive range of pharmaceuticals including specialty biologics, branded medications, generics, and medical consumables to support military medical operations.
Quick answers
Who was awarded contract SPE2DR26FMDU1?
SPE2DR26FMDU1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FMDU1 worth?
The government has obligated $41,008 on SPE2DR26FMDU1.
Is contract SPE2DR26FMDU1 an order under another contract?
Yes. SPE2DR26FMDU1 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDU1 competed?
The extent of competition for SPE2DR26FMDU1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award